Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and Multisystem Inflammatory Syndrome in Children (MIS-C) long-term follow-up
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N91019D00024-P00001-759102000039-2
Grant search
Key facts
Disease
COVID-19Start & end year
20202023Known Financial Commitments (USD)
$18,781,641Funder
National Institutes of Health (NIH)Principal Investigator
GINA MONTEALEGREResearch Location
United States of AmericaLead Research Institution
LEIDOS BIOMEDICAL RESEARCH, INC.Research Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Post acute and long term health consequences
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Randomized Controlled Trial
Broad Policy Alignment
Pending
Age Group
Adolescent (13 years to 17 years)Adults (18 and older)Children (1 year to 12 years)Infants (1 month to 1 year)Newborns (birth to 1 month)
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
This is a multisite prospective observational study to evaluate the clinical sequelae of symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the pediatric population (aged 0-21 years), including coronavirus disease 2019 (COVID-19) and multisystem inflammatory syndrome in children (MIS-C).